Chengdu Zenitar Biomedical Technology Co., Ltd
Clinical trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A single-center, non-randomized, open-label, single-dose mass balance study of [¹⁴C]Purinostat mesylate for injection in healthy participants Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat lymphoma: experimental drug shows promise Results expected Dec 2026 (estimated)
- Can common drugs change how a new cancer medicine works? Results expected Dec 2026 (estimated)
- Can a new experimental pill be safely given to people? Results expected Jul 2027 (estimated)
- New pill could help control blood disorder when standard drugs fail Results expected Jul 2027 (estimated)
-
Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
Disease control Not yet recruitingThis phase 2 trial is testing whether an oral drug called flonoltinib maleate can help adults with myelofibrosis, a rare bone marrow disorder that often causes an enlarged spleen and severe symptoms. The study compares three different daily doses (50 mg, 75 mg, and 100 mg) to see…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking …
Phase 1/2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can common drugs change how a new cancer medicine works?
Knowledge-focused Not yet recruitingThis trial is testing whether two common medications—itraconazole (an antifungal) and rifampicin (an antibiotic)—change how the body processes flonoltinib, an experimental drug being studied for cancer. Healthy adults aged 18 to 45 will take flonoltinib alone and then again with …
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
A single-center, non-randomized, open-label, single-dose mass balance study of [¹⁴C]Purinostat mesylate for injection in healthy participants
Not yet recruitingThis trial adopts a single-center, open-label, non-randomized, single-dose study design. It is planned to enroll 6 healthy Chinese male participants, and the final standard is to collect complete samples and data to be tested from at least 6 participants. After each participant …
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
Last updated Sep 10, 2026 06:00 UTC